Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

Cancer Immunology, Immunotherapy

Volumn 61, Issue 5, 2012, Pages 733-737

  Shahabi, Vafa ^a   Whitney, Gena ^a   Hamid, Omid ^b   Schmidt, Henrik ^c   Chasalow, Scott D ^a   Alaparthy, Suresh ^a   Jackson, Jeffrey R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Angeles Clinic and Research Institute   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

BRAF V600E; CTLA 4; Ipilimumab; Vemurafenib

Indexed keywords

B RAF KINASE; IPILIMUMAB;

ARTICLE; BRAF V600F GENE; CANCER STAGING; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TUMOR BIOPSY; WILD TYPE;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84862494584     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1227-3     Document Type: Article

References (26)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723
2. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D (2003) Braf mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95(8):625-627 (Pubitemid 36553510)
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N et al (2002) Mutations of the braf gene in human cancer. Nature 417(6892):949-954 (Pubitemid 34716871)
4. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S (2003) Braf mutations in papillary carcinomas of the thyroid. Oncogene 22(41):6455-6457 (Pubitemid 37281692)
5. Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, Oechsle K, Steyerberg E, Hartmann JT, Dinjens WN, Oosterhuis JW et al (2009) Microsatellite instability, mismatch repair deficiency, and braf mutation in treatment-resistant germ cell tumors. J Clin Oncol 27(13):2129-2136
6. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, Armengol M, Yamamoto H, Hamelin R, Seruca R, Schwartz S Jr (2003) Braf mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22(57):9192-9196 (Pubitemid 38067995)
7. Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih IM (2003) Mutations in braf and kras characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95(6):484-486 (Pubitemid 36432423)
8. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C (2003) Mutations of the braf gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52(5):706-712 (Pubitemid 36528874)
9. Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA, Burgart LJ, McDonnell SK, Schaid DJ, Thibodeau SN (2003) Braf mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 63(17):5209-5212 (Pubitemid 37139829)
10. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA et al (2002) Similarity of the phenotypic patterns associated with braf and kras mutations in colorectal neoplasia. Cancer Res 62(22):6451-6455 (Pubitemid 35364105)
11. Singh M, Lin J, Hocker TL, Tsao H (2008) Genetics of melanoma tumorigenesis. Br J Dermatol 158(1):15-21 (Pubitemid 350221925)
12. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated braf in metastatic melanoma. N Engl J Med 363(9):809-819
13. Livingstone E, Zimmer L, Piel S, Schadendorf D (2010) Plx4032: Does it keep its promise for metastatic melanoma treatment? Expert Opin Investig Drugs 19(11):1439-1449
14. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T et al (2010) Raf inhibitors prime wild-type raf to activate the mapk pathway and enhance growth. Nature 464(7287):431-435
15. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R (2010) Kinase-dead braf and oncogenic ras cooperate to drive tumor progression through craf. Cell 140(2):209-221
16. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N (2010) Raf inhibitors transactivate raf dimers and erk signalling in cells with wild-type braf. Nature 464(7287):427-430
17. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G et al (2008) Ctla-4 blockade enhances polyfunctional ny-eso-1 specific t cell responses in metastatic melanoma patients with clinical benefit. Proc Nat Acad Sci USA 105(51):20410-20415
18. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gomez H, Bastholt L, Chasalow SD et al (2011) A prospective phase ii trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9(1):204
19. Benlloch S, Paya A, Alenda C, Bessa X, Andreu M, Jover R, Castells A, Llor X, Aranda FI, Massuti B (2006) Detection of braf v600e mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 8(5):540-543 (Pubitemid 44774151)
20. Hamid O, Chasalow S, Tsuchihashi Z, et al. (2009) Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol 27(Suppl), Abstract 9008
21. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) Nras and braf mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9(17):6483-6488 (Pubitemid 38031837)
22. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G et al (2003) High frequency of braf mutations in nevi. Nat Genet 33(1):19-20 (Pubitemid 36068675)
23. Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, van Belle P, Hotz S, Elder DE, Marincola FM, Schuchter L et al (2006) Human leukocyte antigen-a2-restricted ctl responses to mutated braf peptides in melanoma patients. Cancer Res 66(6):3287-3293
24. Eggermont AM (2010) Advances in systemic treatment of melanoma. Ann Oncol 21(Suppl 7):vii339-vii344
25. Weber J (2008) Overcoming immunologic tolerance to melanoma: targeting ctla-4 with ipilimumab (mdx-010). Oncologist 13(Suppl 4):16-25
26. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H et al (2010) Selective brafv600e inhibition enhances t-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70(13):5213-5219